John T Vaage
Overview
Explore the profile of John T Vaage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
365
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orbo H, de Matos Kasahara T, Wolf A, Bjorlykke K, Sexton J, Jyssum I, et al.
Lancet Reg Health Eur
. 2024 Dec;
48:101121.
PMID: 39624496
Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was...
2.
Tunheim G, Fossum E, Robertson A, Ro G, Chopra A, Vaage J, et al.
BMC Infect Dis
. 2024 Aug;
24(1):841.
PMID: 39164637
Background: According to Norwegian registries, 91% of individuals ≥ 16 years had received ≥ 1 dose of COVID-19 vaccine by mid-July 2022, whereas less than 2% of children < 12...
3.
Wusthoff L, Lund-Johansen F, Henriksen K, Wildendahl G, Jacobsen J, Gomes L, et al.
Harm Reduct J
. 2024 Jun;
21(1):120.
PMID: 38890611
Background: During the initial wave of the COVID-19 pandemic, there was a surprisingly low incidence of SARS-CoV-2 among People Who Use Drugs (PWUD) in Oslo, Norway, despite their heightened vulnerability...
4.
Orbo H, Bjorlykke K, Sexton J, Jyssum I, Tveter A, Christensen I, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38599653
Objectives: To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients...
5.
Gainullin M, Federico L, Osen J, Chaban V, Kared H, Alirezaylavasani A, et al.
Front Immunol
. 2024 Feb;
14:1235210.
PMID: 38299149
People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the...
6.
Hovd M, Asberg A, Munthe L, Heldal K, Reisaeter A, Vaage J, et al.
EClinicalMedicine
. 2023 Jun;
60:102035.
PMID: 37362086
Background: Kidney transplant recipients (KTRs) experienced reduced SARS-CoV-2 vaccine response and were at increased risk of severe COVID-19. It is unknown if level of vaccine induced anti-receptor binding domain IgG...
7.
Meyer S, Blaas I, Bollineni R, Delic-Sarac M, Tran T, Knetter C, et al.
Cell Rep
. 2023 Jan;
42(1):111995.
PMID: 36656713
The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that mediate escape from neutralizing antibodies. There is also evidence that mutations can cause loss of T cell...
8.
Bjorlykke K, Orbo H, Tveter A, Jyssum I, Sexton J, Tran T, et al.
Lancet Rheumatol
. 2022 Nov;
5(1):e36-e46.
PMID: 36415604
Background: Data on response and safety of repeated vaccinations and hybrid immunity in patients with immune-mediated inflammatory diseases on immunosuppressive therapy is needed to further develop vaccination strategies in this...
9.
Ibsen J, Chopra A, Vaage E, Vaage J, Lund-Johansen F, Lundin K
Scand J Gastroenterol
. 2022 Sep;
58(2):142-147.
PMID: 36049123
Background And Aims: SARS-CoV-2 infection and development of the disease COVID-19 is a serious threat to our society. Effective vaccines have now entered the market, but most patient populations were...
10.
Syversen S, Jyssum I, Tveter A, Tran T, Sexton J, Provan S, et al.
Arthritis Rheumatol
. 2022 May;
74(8):1321-1332.
PMID: 35507355
Objective: Immunogenicity and safety following receipt of the standard SARS-CoV-2 vaccination regimen in patients with immune-mediated inflammatory diseases (IMIDs) are poorly characterized, and data after receipt of the third vaccine...